Literature DB >> 18588298

Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors.

Kristin E D Coan1, Brian K Shoichet.   

Abstract

Many false positives in early drug discovery owe to nonspecific inhibition by colloid-like aggregates of organic molecules. Despite their prevalence, little is known about aggregate concentration, structure, or dynamic equilibrium; the binding mechanism, stoichiometry with, and affinity for enzymes remain uncertain. To investigate the elementary question of concentration, we counted aggregate particles using flow cytometry. For seven aggregate-forming molecules, aggregates were not observed until the concentration of monomer crossed a threshold, indicating a "critical aggregation concentration" (CAC). Above the CAC, aggregate count increased linearly with added organic material, while the particles dispersed when diluted below the CAC. The concentration of monomeric organic molecule is constant above the CAC, as is the size of the aggregate particles. For two compounds that form large aggregates, nicardipine and miconazole, we measured particle numbers directly by flow cytometry, determining that the aggregate concentration just above the CAC ranged from 5 to 30 fM. By correlating inhibition of an enzyme with aggregate count for these two drugs, we determined that the stoichiometry of binding is about 10,000 enzyme molecules per aggregate particle. Using measured volumes for nicardipine and miconazole aggregate particles (2.1 x 10(11) and 4.7 x 10(10) A(3), respectively), computed monomer volumes, and the observation that past the CAC all additional monomer forms aggregate particles, we find that aggregates are densely packed particles. Finally, given their size and enzyme stoichiometry, all sequestered enzyme can be comfortably accommodated on the surface of the aggregate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18588298      PMCID: PMC2627561          DOI: 10.1021/ja802977h

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  26 in total

1.  Inhibition of voltage-dependent sodium channels by Ro 31-8220, a 'specific' protein kinase C inhibitor.

Authors:  R Lingameneni; T N Vysotskaya; D S Duch; H C Hemmings
Journal:  FEBS Lett       Date:  2000-05-12       Impact factor: 4.124

2.  Development of a virtual screening method for identification of "frequent hitters" in compound libraries.

Authors:  Olivier Roche; Petra Schneider; Jochen Zuegge; Wolfgang Guba; Manfred Kansy; Alexander Alanine; Konrad Bleicher; Franck Danel; Eva-Maria Gutknecht; Mark Rogers-Evans; Werner Neidhart; Henri Stalder; Michael Dillon; Eric Sjögren; Nader Fotouhi; Paul Gillespie; Robert Goodnow; William Harris; Phil Jones; Mikio Taniguchi; Shinji Tsujii; Wolfgang von der Saal; Gerd Zimmermann; Gisbert Schneider
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

3.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening.

Authors:  Susan L McGovern; Emilia Caselli; Nikolaus Grigorieff; Brian K Shoichet
Journal:  J Med Chem       Date:  2002-04-11       Impact factor: 7.446

4.  Kinase inhibitors: not just for kinases anymore.

Authors:  Susan L McGovern; Brian K Shoichet
Journal:  J Med Chem       Date:  2003-04-10       Impact factor: 7.446

5.  Identification and prediction of promiscuous aggregating inhibitors among known drugs.

Authors:  James Seidler; Susan L McGovern; Thompson N Doman; Brian K Shoichet
Journal:  J Med Chem       Date:  2003-10-09       Impact factor: 7.446

Review 6.  Nonleadlikeness and leadlikeness in biochemical screening.

Authors:  Gilbert M Rishton
Journal:  Drug Discov Today       Date:  2003-01-15       Impact factor: 7.851

7.  Effect of detergent on "promiscuous" inhibitors.

Authors:  Ali J Ryan; Norman M Gray; Peter N Lowe; Chun-wa Chung
Journal:  J Med Chem       Date:  2003-07-31       Impact factor: 7.446

8.  A specific mechanism of nonspecific inhibition.

Authors:  Susan L McGovern; Brian T Helfand; Brian Feng; Brian K Shoichet
Journal:  J Med Chem       Date:  2003-09-25       Impact factor: 7.446

9.  Small-molecule aggregates inhibit amyloid polymerization.

Authors:  Brian Y Feng; Brandon H Toyama; Holger Wille; David W Colby; Sean R Collins; Barnaby C H May; Stanley B Prusiner; Jonathan Weissman; Brian K Shoichet
Journal:  Nat Chem Biol       Date:  2008-01-27       Impact factor: 15.040

10.  Molecular properties that influence the oral bioavailability of drug candidates.

Authors:  Daniel F Veber; Stephen R Johnson; Hung-Yuan Cheng; Brian R Smith; Keith W Ward; Kenneth D Kopple
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

View more
  87 in total

1.  Solubility at the molecular level: development of a critical aggregation concentration (CAC) assay for estimating compound monomer solubility.

Authors:  Jie Wang; Edmund Matayoshi
Journal:  Pharm Res       Date:  2012-03-16       Impact factor: 4.200

2.  Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4.

Authors:  Michael M Mysinger; Dahlia R Weiss; Joshua J Ziarek; Stéphanie Gravel; Allison K Doak; Joel Karpiak; Nikolaus Heveker; Brian K Shoichet; Brian F Volkman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

3.  Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors.

Authors:  Abhinav Nath; Michael A Zientek; Benjamin J Burke; Ying Jiang; William M Atkins
Journal:  Drug Metab Dispos       Date:  2010-09-14       Impact factor: 3.922

4.  Self-assembling small molecules form nanofibrils that bind procaspase-3 to promote activation.

Authors:  Julie A Zorn; Holger Wille; Dennis W Wolan; James A Wells
Journal:  J Am Chem Soc       Date:  2011-11-17       Impact factor: 15.419

Review 5.  Docking Screens for Novel Ligands Conferring New Biology.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Med Chem       Date:  2016-03-15       Impact factor: 7.446

6.  Divergent modes of enzyme inhibition in a homologous structure-activity series.

Authors:  Rafaela S Ferreira; Clifford Bryant; Kenny K H Ang; James H McKerrow; Brian K Shoichet; Adam R Renslo
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

7.  Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide.

Authors:  Yun Wang; Arthur F Monzingo; Shougang Hu; Tera H Schaller; Jon D Robertus; Walter Fast
Journal:  Biochemistry       Date:  2009-09-15       Impact factor: 3.162

8.  Identification of small-molecule enhancers of arginine methylation catalyzed by coactivator-associated arginine methyltransferase 1.

Authors:  Sabrina Castellano; Astrid Spannhoff; Ciro Milite; Fabrizio Dal Piaz; Donghang Cheng; Alessandra Tosco; Monica Viviano; Abdellah Yamani; Agostino Cianciulli; Marina Sala; Vincent Cura; Jean Cavarelli; Ettore Novellino; Antonello Mai; Mark T Bedford; Gianluca Sbardella
Journal:  J Med Chem       Date:  2012-11-02       Impact factor: 7.446

9.  Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease.

Authors:  Ajit Jadhav; Rafaela S Ferreira; Carleen Klumpp; Bryan T Mott; Christopher P Austin; James Inglese; Craig J Thomas; David J Maloney; Brian K Shoichet; Anton Simeonov
Journal:  J Med Chem       Date:  2010-01-14       Impact factor: 7.446

10.  Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor.

Authors:  Jianxiong Jiang; Thota Ganesh; Yuhong Du; Pahk Thepchatri; Asheebo Rojas; Iestyn Lewis; Serdar Kurtkaya; Lian Li; Min Qui; Geidy Serrano; Renee Shaw; Aiming Sun; Ray Dingledine
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.